Frequency of Tuberculosis in Psoriasis Patients

Bezmialem Vakif University

Status: Completed

Conditions: Tuberculosis; Psoriasis Vulgaris

Study type: Observational

Funder types: Other

Identifiers

NCT06563635

E-54022451-050.05.04-116589

Details and patient eligibility

About

Aim of this study is evaluation of patients receiving TNF inhibitor therapy in terms of tuberculosis at the end of 15 years in a single center.

Full description

Aim of this study is evaluation of patients receiving TNF inhibitor therapy in terms of tuberculosis at the end of 15 years in a single center. TNF inhibitor therapy may increase the risk for tuberculosis infection. According to medical data in our hospital in last 15 years, tuberculosis rate of psoriasis patients receiving etanercept, adalimumab and infliximab will be compared.

Enrollment: 719 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• psoriasis patients receiving TNF inhibitor therapy

Exclusion criteria

• patients without TNF inhibitor therapy

Trial design

719 participants in 3 patient groups

etanercept

Description:

psoriasis patients receiving etanercept therapy

infliximab

Description:

psoriasis patients receiving infliximab therapy

adalimumab

Description:

psoriasis patients receiving adalimumab therapy